Biopharmaceuticals Has Been Established Innovative Technology Platform

Biopharmaceuticals Has Been Established Innovative Technology Platform

Biopharmaceuticals are medical drugs produced using biotechnology. They are proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic purposes. Currently, innovation in biopharmaceuticals require complex knowledge base, ongoing exploration, and expensive processes, amplified by great uncertainties.

Combining AlfaCell® site-specific integration platform for cell line development and AlfaMedX® AI-enabled platform for culture media development, Great Bay Bio provides one-stop bioproduction solutions that achieve robust cell growth, improve recombinant protein yield and ensure high quality for therapeutic antibodies, growth factors, Fc Fusions, and enzyme production.

Product Detail

Product Tags


AI-enabled Pro-antibody Design Platform



AI-enabled Site-Specific Integration Cell Line Development Platform


Al-enabled Cell Culture Media Development Platform

Biopharmaceuticals are pharmaceuticals produced using biotechnology, a set of techniques that involve the manipulation of living organisms to produce products that have a medicinal value. Examples of biopharmaceuticals include monoclonal antibodies, interferons, recombinant hormones, and vaccines. These products are used to treat a wide range of medical conditions, such as cancer, HIV/AIDS, diabetes, and heart disease. Unlike traditional drugs, which are usually synthesized in a laboratory, biopharmaceuticals are produced by genetically modifying living organisms, such as bacteria and yeast, to produce the desired substances. This process requires sophisticated equipment and highly trained technicians, and is much more expensive than traditional drug production. Despite the high cost, biopharmaceuticals are becoming increasingly popular as they are often more effective than traditional drugs, and can be tailored to specific medical needs.


The core team of GBB is composed of global talents with expertise in medicine, pharmacy, synthetic biology and AI. With a 3000 m2 R&D center and CMC platform, GBB has successfully pushed several biological drugs into the NDA stage, including national class 1 new drugs. During the four years since its establishment, GBB has applied for more than 30 patents for its AI empowered bioprocesses solutions. The resulting AI platforms were successfully commercialized, enabling GBB to establish long-term cooperation with many domestic and foreign leading enterprises.

  • Previous:
  • Next:

  • Write your message here and send it to us